AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10470637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand with ‐0.5 cm and 0 cm extrusion
Number of subjects: 270
Study 10470637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand with extrusion > or = 3 cm
Number of subjects: 270
Study 10470637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand bent at 40 degrees to 60 degrees with extrusion of 1 to 2 cm
Number of subjects: 270
Study 10470637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand for obese patients with body weight > or = 120% of the standard
Number of subjects: 270
Study 8807065 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli isolates resistant to ampicillin
Number of subjects: 20
Study 8807065 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli isolates resistant to trimethoprim
Number of subjects: 20
Study 8807065 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli isolates resistant to tetracycline
Number of subjects: 20
Study 8807065 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous resistance to more than one antibiotic by E. coli isolates
Number of subjects: 20
Study 8807065 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent fecal shedding of resistant E. coli
Number of subjects: 20
Study 8807065 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization by E. coli resistant to chloramphenicol, gentamicin, nitrofurantoin, or norfloxacin
Number of subjects: 20
Study 8807065 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization by Klebsiella species and Shigella species resistant to antibiotics
Number of subjects: 20
Study 1863002 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-way system including hydrophilic polymer-coated catheter, daily catheter care, and disinfection with povidone-iodine
Number of subjects: 606
Study 1863002 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 606
Study 6821866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision or biopsy followed by local radiotherapy and randomization to chemotherapy regimens (protocol IESS 7299)
Number of subjects: 36
Study 6821866 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete surgical excision of the primary lesion
Number of subjects: 36
Study 6821866 — intervention group
Group type: COMPARATOR
Intervention: Partial excision or biopsy
Number of subjects: 36
Study 6821866 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol IESS 7450 (radiotherapy to all areas of known disease and four drug chemotherapy)
Number of subjects: 36
Study 31927509 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing Trauma Awareness course
Number of subjects: 100
Study 31539335 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach (ad hoc, rigid suction catheter airway decontamination)
Number of subjects: 31
Study 31539335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional esophageal intubation (IEI)
Number of subjects: 31
Study 31539335 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction-assisted laryngoscopy and airway decontamination (SALAD)
Number of subjects: 31
Study 31539335 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach
Number of subjects: 31
Study 31539335 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 31
Study 27368672 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose tenapanor 180 mg
Number of subjects: 32
Study 27368672 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-dose tenapanor 15, 30, 60, or 90 mg twice daily for 7 days
Number of subjects: 32
Study 27368672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26318355 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 502
Study 26318355 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 502
Study 26318355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 502
Study 27128839 — intervention group
Group type: COMPARATOR
Intervention: Crushed rivaroxaban tablet in applesauce suspension (Crushed‐Oral)
Number of subjects: 55
Study 27128839 — intervention group
Group type: COMPARATOR
Intervention: Crushed rivaroxaban tablet in water suspension via NG tube (Crushed‐NG)
Number of subjects: 55
Study 27128839 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole rivaroxaban tablet (Reference [Whole‐Oral])
Number of subjects: 55
Study 23094903 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic control (80‐140 mg/dL)
Number of subjects: 40
Study 23094903 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (180‐200 mg/dL)
Number of subjects: 40
Study 19713801 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy for 30 minutes on 3 consecutive days
Number of subjects: 120
Study 19713801 — intervention group
Group type: COMPARATOR
Intervention: Usual care (30-minute rest on 3 consecutive days)
Number of subjects: 120
Study 17240225 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (n = 74)
Number of subjects: 153
Study 17240225 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 153
Study 17240225 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 79)
Number of subjects: 153
Study 15038639 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulator training (6-10 hours)
Number of subjects: 68
Study 15038639 — intervention group
Group type: COMPARATOR
Intervention: Traditional preclinical dentistry laboratory training
Number of subjects: 68
Study 11346860 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 0
Study 11346860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9165384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 144
Study 8196433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative anesthesia of the ilioinguinal and iliohypogastric nerves with a long-acting local anesthetic combined with a vasoconstrictor
Number of subjects: 150000
Study 8196433 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control intervention was)
Number of subjects: 150000
Study 3467505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser iridotomy
Number of subjects: 29
Study 3467505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye laser iridotomy
Number of subjects: 29
Study 3467505 — intervention group
Group type: COMPARATOR
Intervention: Surgical peripheral iridectomy
Number of subjects: 29
Study 3467505 — intervention group
Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 29
Study 30095360 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (St. Thomas' Harefield preparation)
Number of subjects: 44
Study 30095360 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia at 4-6°C
Number of subjects: 44
Study 30095360 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cooling
Number of subjects: 44
Study 30095360 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction and maintenance dosing
Number of subjects: 44
Study 30095360 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-dosing interval
Number of subjects: 44
Study 30095360 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate in a trial
Number of subjects: 44
Study 30095360 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia
Number of subjects: 44
Study 29983113 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker home visiting during antenatal and postnatal periods
Number of subjects: 1320
Study 29983113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1320
Study 26574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO) anesthesia maintained with 2 MAC and nitrous oxide 50%
Number of subjects: 60
Study 26574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO) anesthesia maintained with 2 MAC and nitrous oxide 50%
Number of subjects: 60
Study 26574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 60
Study 26574871 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 60
Study 24311703 — intervention group
Group type: EXPERIMENTAL
Intervention: New TRO-CTA protocol (non-ECG-gated low kVp scan at 80 kVp)
Number of subjects: 60
Study 24311703 — intervention group
Group type: COMPARATOR
Intervention: Conventional TRO-CTA protocol (retrospective ECG-gating at 120 kVp)
Number of subjects: 60
Study 23795897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 8884
Study 23795897 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 8884
Study 23795897 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ST-segment depression (1.0 mm vs no/0.5 mm)
Number of subjects: 8884
Study 23795897 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ST-segment depression (>1.0 mm)
Number of subjects: 8884
Study 23795897 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge ST-segment depression (1.0 mm)
Number of subjects: 8884
Study 23795897 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge ST-segment depression (>1.0 mm)
Number of subjects: 8884
Study 21092177 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein panel (total PSA, free PSA, intact PSA, hK2)
Number of subjects: 262
Study 21092177 — intervention group
Group type: COMPARATOR
Intervention: Base model (PSA, age, DRE)
Number of subjects: 262
Study 19034332 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day (ATV)
Number of subjects: 26
Study 19034332 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day + Amlodipine 20 mg/day (ATV+AML)
Number of subjects: 26
Study 16819567 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostable autohemoderivative
Number of subjects: 108
Study 16819567 — intervention group
Group type: COMPARATOR
Intervention: Adequate measures to be comparable control
Number of subjects: 108
Study 14600515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus-specific IFN-gamma production
Number of subjects: 26
Study 14600515 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART duration
Number of subjects: 26
Study 14600515 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV viral load
Number of subjects: 26
Study 14600515 — intervention group
Group type: COMPARATOR
Intervention: Control group (26 randomly selected individuals)
Number of subjects: 26
Study 14600515 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell counts, cytomegalovirus lymphocyte proliferation, IL-2, and IL-10
Number of subjects: 26
Study 10898421 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 154
Study 10898421 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 154
Study 10898421 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-hirudin
Number of subjects: 154
Study 10898421 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 154
Study 10898421 — intervention group
Group type: COMPARATOR
Intervention: Composite end point (death, myocardial infarction, revascularization)
Number of subjects: 154
Study 10898421 — intervention group
Group type: COMPARATOR
Intervention: One-month mortality
Number of subjects: 154
Study 8882962 — intervention group
Group type: EXPERIMENTAL
Intervention: P-VEBEC regimen (epirubicin 50 mg/sqm, cyclophosphamide 300 mg/sqm, etoposide 100 mg/sqm on weeks 1, 3, 5, 7; vinblastine 5 mg/sqm and bleomycin 5 mg/sqm on weeks 2, 4, 6, 8; prednisone 50 mg/sqm/day for the first two weeks and then every other day) with rG-CSF 5 micrograms/Kg/day for 4 consecutive days starting on day 2 of every week.
Number of subjects: 100
Study 8882962 — intervention group
Group type: COMPARATOR
Intervention: P-VEBEC regimen without rG-CSF (implied control group).
Number of subjects: 100
Study 8882962 — intervention group
Group type: EXPERIMENTAL
Intervention: P-VEBEC regimen with rG-CSF.
Number of subjects: 100
Study 8882962 — intervention group
Group type: EXPERIMENTAL
Intervention: P-VEBEC regimen in patients with diffuse large cell lymphomas (DLCL).
Number of subjects: 100
Study 1563574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg promegestone
Number of subjects: 132
Study 1563574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg promegestone
Number of subjects: 132
Study 1563574 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lynestrenol
Number of subjects: 132
Study 7472109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid treatment
Number of subjects: 2
Study 7472109 — intervention group
Group type: COMPARATOR
Intervention: Control (no ascorbic acid)
Number of subjects: 2
Study 31959340 — intervention group
Group type: EXPERIMENTAL
Intervention: DCF (docetaxel, cisplatin, and fluorouracil)
Number of subjects: 124
Study 31959340 — intervention group
Group type: EXPERIMENTAL
Intervention: DCFRT (docetaxel, cisplatin, fluorouracil + 45 Gy radiotherapy)
Number of subjects: 124
Study 31959340 — intervention group
Group type: COMPARATOR
Intervention: EMR (early metabolic response)
Number of subjects: 124
Study 31117111 — intervention group
Group type: EXPERIMENTAL
Intervention: AI malignant probability using deep learning algorithms
Number of subjects: 0
Study 31117111 — intervention group
Group type: EXPERIMENTAL
Intervention: AI malignant probability
Number of subjects: 0
Study 28026777 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive P300-based BCI application with proprioceptive stimulation
Number of subjects: 2
Study 28026777 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive feedback
Number of subjects: 2
Study 28026777 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy subjects
Number of subjects: 2
Study 26104068 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO intervention
Number of subjects: 57
Study 26104068 — intervention group
Group type: COMPARATOR
Intervention: Standard home visitation program
Number of subjects: 57
Study 23882708 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin intrinsic fluorescence (SIF) measurement
Number of subjects: 1185
Study 23882708 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of clinical and technical factors
Number of subjects: 1185
Study 21853612 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion solution 'potassium and magnesium asparginate' at a rate of 1.5-2 ml/kg/h (n = 44)
Number of subjects: 77
Study 21853612 — intervention group
Group type: COMPARATOR
Intervention: Magnesium free crystalloid solutions (n = 33)
Number of subjects: 77
Study 19320673 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based assessment and feedback (THRIVE)
Number of subjects: 7237
Study 19320673 — intervention group
Group type: COMPARATOR
Intervention: Screening alone (Control)
Number of subjects: 7237
Study 18174969 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazax (Timothy-grass pollen extract) administered sublingually
Number of subjects: 0
Study 18174969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16948861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis formulation (two daily doses)
Number of subjects: 123
Study 16948861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis formulation with diet (2100‐2200 calories/day)
Number of subjects: 123
Study 16948861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 16948861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis formulation without diet
Number of subjects: 123
Study 16948861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis formulation (no diet)
Number of subjects: 123
Study 12901993 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (Fuji Plus)
Number of subjects: 29
Study 12901993 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite (Panavia 21)
Number of subjects: 29
Study 10583024 — intervention group
Group type: COMPARATOR
Intervention: Risedronate administered 2 h after dinner
Number of subjects: 127
Study 10583024 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate administered 1 h before a meal
Number of subjects: 127
Study 10583024 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate administered 0.5 h before a meal
Number of subjects: 127
Study 10583024 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate administered 4 h before a meal
Number of subjects: 127
Study 9139271 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart infarction with Q wave (group I)
Number of subjects: 80
Study 9139271 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart infarction without Q wave (group II)
Number of subjects: 80
Study 9139271 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 80
Study 1819621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g intravenously or intramuscularly, twice daily)
Number of subjects: 76
Study 1819621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (1 g intravenously or intramuscularly, twice daily)
Number of subjects: 76
Study 1819621 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (500 mg intravenously or intramuscularly, twice daily)
Number of subjects: 76
Study 6291832 — intervention group
Group type: EXPERIMENTAL
Intervention: MK 421 (10 mg p.o.)
Number of subjects: 12
Study 29626552 — intervention group
Group type: EXPERIMENTAL
Intervention: Call it Quits intervention (five-session program delivered by case-workers)
Number of subjects: 431
Study 29626552 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 431
Study 28581397 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemo-IMRT
Number of subjects: 102
Study 28581397 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemo-IMRT alone
Number of subjects: 102
Study 28581397 — intervention group
Group type: EXPERIMENTAL
Intervention: V40 > 85%
Number of subjects: 102
Study 28581397 — intervention group
Group type: COMPARATOR
Intervention: V40 ≤ 85%
Number of subjects: 102
Study 24028173 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB-based intervention in 18 intervention schools
Number of subjects: 2021
Study 24028173 — intervention group
Group type: COMPARATOR
Intervention: Control group in 26 control schools
Number of subjects: 2021
Study 23254543 — intervention group
Group type: EXPERIMENTAL
Intervention: SBST (static stretching before each strength training session)
Number of subjects: 30
Study 23254543 — intervention group
Group type: EXPERIMENTAL
Intervention: SDST (static stretching before each training set)
Number of subjects: 30
Study 23254543 — intervention group
Group type: COMPARATOR
Intervention: OST (no stretching exercise)
Number of subjects: 30
Study 21925996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg
Number of subjects: 489
Study 21925996 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 489
Study 18179455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Number of subjects: 0
Study 18179455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15867121 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a learning collaborative project based on the Breakthrough Series methodology of continuous quality improvement
Number of subjects: 13878
Study 15867121 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13878
Study 14559422 — intervention group
Group type: EXPERIMENTAL
Intervention: Release from lower height (one‐knee height)
Number of subjects: 10
Study 14559422 — intervention group
Group type: COMPARATOR
Intervention: Release from higher height (three‐quarters of knee to shoulder distance)
Number of subjects: 10
Study 14559422 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing release load (20, 40, 60, 80 N) at lower height
Number of subjects: 10
Study 14559422 — intervention group
Group type: COMPARATOR
Intervention: Increasing release load (20, 40, 60, 80 N) at higher height
Number of subjects: 10
Study 9892313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular flunitrazepam (1 mg i.m.)
Number of subjects: 28
Study 9892313 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol (5 mg i.m.)
Number of subjects: 28
Study 8694035 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (micronized estradiol, 2 mg/day)
Number of subjects: 31
Study 8694035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1911460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 32
Study 1911460 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 32
Study 7112304 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable skin stapler (Proximate; Ethicon)
Number of subjects: 0
Study 7112304 — intervention group
Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 0
Study 31448928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 40
Study 31448928 — intervention group
Group type: COMPARATOR
Intervention: Coding training (active control)
Number of subjects: 40
Study 27553981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing relaxation (DBR) training program
Number of subjects: 0
Study 26504795 — intervention group
Group type: EXPERIMENTAL
Intervention: HCARE (high-concentration ashwagandha root extract) 300mg twice daily for 8 weeks
Number of subjects: 50
Study 26504795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch) 300mg twice daily for 8 weeks
Number of subjects: 50
Study 23829946 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating (HE)
Number of subjects: 880
Study 23829946 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 880
Study 23829946 — intervention group
Group type: EXPERIMENTAL
Intervention: HE + PA
Number of subjects: 880
Study 23829946 — intervention group
Group type: EXPERIMENTAL
Intervention: HE + PA + Vitamin D
Number of subjects: 880
Study 23829946 — intervention group
Group type: EXPERIMENTAL
Intervention: HE + PA + Placebo
Number of subjects: 880
Study 23829946 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D alone (1600 IU)
Number of subjects: 880
Study 23829946 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo alone
Number of subjects: 880